1 results
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2023-506926-35-00 check the CTIS register for the current data. The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined…